Rapacuronium

DB04834ApprovedWithdrawnSmall molecule

Rapacuronium is a nondepolarizing neuromuscular blocking agent used as an adjunct to general anesthesia to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgical procedures. Rapacuronium was withdrawn in 2001 in many countries due to risk of fatal bronchospasm.

Mechanism: Pharmacologically active on Muscarinic acetylcholine receptor M2
Curator reviewed
Primary indication: Used in anaesthesia, to aid and enable endotracheal intubation.Curator reviewed
Formula / weight: C₃₇H₆₁N₂O₄ · 597.904 g/mol (avg)
First approval: United States, 1999

Resolves to

Compound

UNIIGG1LBM463SCAS465499-11-0ChEMBLCHEMBL1201352ChEBI135845PubChem5311399

Clinical / RWD

RxNorm262100PharmGKBPA451227

Structure

InChIKeyHTIKWNNIPGXLGM-YLINKJIISA-NSMILES

[H][C@@]12C[C@@H]([C@H](OC(=O)CC)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](OC(C)=O)[C@H](C[C@]12C)N1CCCCC1)[N+]1(CC=C)CCCCC1

Targets

P08172CHRM2

What you can answer from here — as of September 13, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1,220Drug interactionsStructured to mechanism, not free text

2Marketed productsAcross 1 country and 1 labeller

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Rapacuronium, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account